Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 296INDUSTRY 262NIH 23OTHER_GOV 8UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 42Esophageal Neoplasms 24Stomach Neoplasms 21Rectal Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Colorectal Neoplasms 12Neoplasms 10Lung Neoplasms 10Brain Neoplasms 10Triple Negative Breast Neoplasms 9Small Cell Lung Carcinoma 8Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Nasopharyngeal Carcinoma 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Hepatocellular 5Recurrence 4Radiation Injuries 4Melanoma 4Lymphoma, Extranodal NK-T-Cell 4Head and Neck Neoplasms 4Uterine Cervical Neoplasms 3Meningeal Carcinomatosis 3Lymphoma 3Leukemia, Myeloid, Acute 3Hormone Receptor Positive Advanced Breast Cancer 3HER2-positive Breast Cancer 3Colonic Neoplasms 3Vomiting 2

Interventions

pyrotinib 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Carcinoma, Transitional Cell × Clear all
NCT05318339 2022-04-08

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

ChineseAMS

Phase 2 Unknown
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡